Skip to main content
. Author manuscript; available in PMC: 2019 Sep 15.
Published in final edited form as: J Immunol. 2018 Jul 30;201(6):1692–1704. doi: 10.4049/jimmunol.1800244

FIGURE 4.

FIGURE 4.

PreproB cells that expresses a Cebpa +37 kb enhancer/promoter transgene have B cell and myeloid potential. (A) Diagram of the Cebpa +37 kb enhancer/promoter-hCD4 transgene (left) and gating strategy to obtain preproB, proB, early preB, and preB cells from these mice (right). (B) Representative CD24/hCD4 FC from Cebpa Enh/prom-hCD4 mice (left) and the proportion of B lineage precursors from these mice that express hCD4 (right, mean and SD from three determinations). (C) Representative CD11b/CD19 FC after culturing hCD4- or hCD4+ preproB cells on OP9-GFP cells with FL and IL-7 on day 3 (D3) or day 5 (D5) and the proportion of these cells that express CD11b or CD19 (mean and SD from three determinations). (D) PreproB cells isolated from the bone marrows of Cebpa Enh(f/f) or Enh(f/f);Mx1-Cre mice exposed 4 wks earlier to pIpC were plated on OP9-GFP cells with FL and IL-7 and analyzed on day 3 for CD11b+Gr-1- monocytes, CD11b+Gr-1+ granulocytes, and for preproB, proB, early preB, and preB cells (mean and SD from three determinations).